Document is current
Any future updates will be listed below
-
Authors
Tohi, Yoichiro
Yokomizo, Akira
Kimura, Takahiro
Wakabayashi, Masashi
Shiota, Masaki
Mori, Keiichiro
Kato, Takuma
Tsuzuki, Toyonori
Kato, Masashi
Sasaki, Keita
Kawahara, Takashi
Eto, Masatoshi
Nishiyama, Hiroyuki
Kitamura, Hiroshi
Sugimoto, Mikio https://orcid.org/0000-0001-9266-782X
,
-
Funding
Funding for this research was provided by:
National Cancer Center Research and Development Fund (2020-J-3, 2023-J-03)
- License Information
-
More Information
Article History
Received: 11 November 2024
Accepted: 24 January 2025
First Online: 8 March 2025
Declarations
:
: Akira Yokomizo received honoraria from Astra Zeneca and Takeda. Takahiro Kimura received honoraria from Astellas, AstraZeneca, Bayer, Janssen, Sanofi, and Takeda. Masaki Shiota received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi, and Bayer Yakuhin. Toyonori Tsuzuki reports honoraria for lectures from AstraZeneca, Bayer Yakuhin, Bristol Myers Squibb, Janssen Pharmaceutical, Merck Biopharma, MSD, Ono Pharmaceutical, Pfizer. Masashi Kato received honoraria from AstraZeneca and Janssen Pharmaceutical; research funding from AstraZeneca; research funding from Astellas Pharma. Masatoshi Eto reports honoraria for lectures from Astellas Pharma, AstraZeneca, Bayer Yakuhin, Bristol Myers Squibb, Eisai, Janssen Pharmaceutical, Merck Biopharma, MSD, Ono Pharmaceutical, Pfizer, and Takeda Pharmaceutical; research funding from Bristol Myers Squibb, MSD, Ono Pharmaceutical, and Takeda Pharmaceutical. Hiroshi Kitamura received honoraria from Astellas, AstraZeneca, Bristol Myers Squibb, Merck Biopharma, MSD, Sanofi, and Takeda; research funding from MSD. Mikio Sugimoto received honoraria from Astellas, AstraZeneca, Bayer, Janssen, Pfizer, Takeda, Nippon Shinyaku.
